Department of Defense (DoD) expense reimbursement contract	12 Months Ended
Dec. 31, 2020
Department of Defense (DoD) expense reimbursement contract
U.S. Department of Defense ("DoD") Expense Reimbursement Grant	5. Department of Defense (DoD) expense reimbursement contract In July 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the DoD Agreement) with the DoD to fund the Company’s efforts in developing Biosynthetic Convalescent Plasma (BCP) to treat COVID-19. Under the DoD Agreement, the Company intends to develop BCP for use in the U.S. military population and the U.S. population as a whole, subject to approval by the U.S. Food and Drug Administration (FDA). The amount of funding being made available to the Company under this expense reimbursement contract is $13.3 million which, based on the Company’s anticipated expenditures, is expected to be received through mid-2021. The Company recorded contra-research and development expense of $1.7 million for the year ended December 31, 2020 in the statements of operations. As of December 31, 2020, the Company had an expense reimbursement receivable balance of $0.9 million due from the DoD in prepaid expenses and other current assets on the balance sheet.

Department of Defense (DoD) expense reimbursement contract

12 Months Ended

Dec. 31, 2020

Department of Defense (DoD) expense reimbursement contract

U.S. Department of Defense ("DoD") Expense Reimbursement Grant

5. Department of Defense (DoD) expense reimbursement contract

In July 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the DoD Agreement) with the DoD to fund the Company’s efforts in developing Biosynthetic Convalescent Plasma (BCP) to treat COVID-19. Under the DoD Agreement, the Company intends to develop BCP for use in the U.S. military population and the U.S. population as a whole, subject to approval by the U.S. Food and Drug Administration (FDA). The amount of funding being made available to the Company under this expense reimbursement contract is $13.3 million which, based on the Company’s anticipated expenditures, is expected to be received through mid-2021. The Company recorded contra-research and development expense of $1.7 million for the year ended December 31, 2020 in the statements of operations. As of December 31, 2020, the Company had an expense reimbursement receivable balance of $0.9 million due from the DoD in prepaid expenses and other current assets on the balance sheet.